
Sign up to save your podcasts
Or
Moderator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.
Moderator: Francesco Di Lorenco (Rome, Italy)
Guest: Dag Aarsland (London, United Kingdom)
Francesco Di Lorenco and Prof. Dag Aarsland discuss managing behavioral symptoms in dementia, highlighting the burden on patients and families. They stress the importance of timely treatment and challenges in diagnosis. They mention brexpiprazole's FDA approval for Alzheimer's agitation and the need for careful monitoring. Early detection of psychiatric symptoms in neurological diseases is crucial, but distinguishing between disorders is challenging. Therapeutic options like clozapine and cholinesterase inhibitors are mentioned, calling for more research and collaboration.
4,335 Listeners
90,779 Listeners
278 Listeners
317 Listeners
35 Listeners
476 Listeners
111,466 Listeners
14 Listeners
21 Listeners
130 Listeners
10 Listeners
44 Listeners
43 Listeners
174 Listeners
74 Listeners